Applied Therapeutics Reports Second Quarter 2025 Financial Results
- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD
How could this news affect the overall sector sentiment for biotech and rare‑disease therapeutics?
Will the Q2 2025 results meet or exceed consensus estimates, and what are the implications if they fall short?
What technical indicators or price patterns suggest the stock could react strongly to this earnings release?
22 days ago